As miR-155 overexpression is observed in various malignancies including that of lung cancer, it has been found that miR-155 inhibition restores sensitivity of lung cancer to cisplatin via negative regulation of Apaf-1 expression [145]. Here, APAF1 is linked to lung carcinoma.